The latest data from the ECHELON-1 trial shows that the use of brentuximab vedotin, plus doxorubicin, vinblastine, and dacarbazine (A+AVD) as first-line treatment for stage III or IV Hodgkin's Lymphoma resulted in long-term progression-free survival benefits when compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

The analysis, published in the New England Journal...